responder analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
=== Non-competitive inhibitor: Strychnine === Strychnine is a neurotoxin that causes death by affecting nerves that control muscular contraction and cause respiration difficulty. The impulse is transmitted between the synapse through a neurotransmitter called acetylcholine. It is released into the synapse between nerve cells and binds to receptors in the postsynaptic cell. Then an action potential is generated and transmitted through the postsynaptic cell to start a new cycle. Glycine can inhibit the activity of neurotransmitter receptors, thus a larger amount of acetylcholinesterase is required to trigger an action potential. This makes sure that the generation of nerve impulses is tightly controlled. However, this control is broken down when strychnine is added. It inhibits glycine receptors(a chloride channel) and a much lower level of neurotransmitter concentration can trigger an action potential. Nerves now constantly transmit signals and cause excessive muscular contraction, leading to asphyxiation and death.
The weakening of the fibrous cap of atheromatous plaques by apoptosis of smooth muscle cells has also been linked to granzyme B. More recently, a key role for extracellular granzyme B has been forwarded for a number of autoimmune (e.g. arthritis, autoimmune blistering, scleroderma, lupus)(Reviewed in ) and/or age-related chronic inflammatory disorders (Photoaging, aneurysm, atherosclerosis, COPD, macular degeneration, etc.)(Reviewed in ). In many of these conditions, proof-of-concept has been demonstrated through the use of experimental models, genetic approaches and/or pharmacologic approaches.
=== Proposed re-engined versions === In the 1980s, there were moves to fit the Il-86 with RB211-22 engines. Designated Il-86V (second use of this designation), this would have had a range of over 9,000 km (4,860 nmi) and/or increased payload. Another 450-seater Il-86V powered by RB211-524G engines was also projected. Amid the disintegration of the Soviet economy, these versions did not progress. In 1991, there were moves to fit the Il-86 with Franco-American CFM56-5C2 engines. Finances precluded progress. In 1995, International Aero Engines offered the V2500 engine to five Il-86 operators with proposals to re-engine 25 aircraft. The offer was not taken up.
Sources: en.wikipedia.org
=== Brent Langer === Special Agent Brent Langer (Jonathan LaPaglia) first appears in the episode "Tribes". He is killed in the episode "Last Man Standing" by Agent Michelle Lee, and initially suspected of being a mole. Lee is, in fact, the mole, as Langer learns, and she kills him to preserve her cover. He was mentored by Gibbs at NCIS before joining the FBI and is transferred back to NCIS at Gibbs' recommendation. He works with Gibbs' team in the episode "Tribes", where he assists the team in tracking down a terrorist recruiter. Gibbs places his voided FBI agent ID card on a wall commemorating fallen personnel in the episode, "Collateral Damage", just as Gibbs is turning his suspicion back to Agent Lee.
== Other elements usually produced through synthesis == All elements with atomic numbers 1 through 94 occur naturally at least in trace quantities, but the following elements are often produced through synthesis.
Morphine, the archetypal opioid, and other opioids (e.g., codeine, oxycodone, hydrocodone, dihydromorphine, pethidine) all exert a similar influence on the cerebral opioid receptor system. Buprenorphine is a partial agonist of the μ-opioid receptor, and tramadol is a serotonin–norepinephrine reuptake inhibitor (SNRI) with weak μ-opioid receptor agonist properties. Tramadol is structurally closer to venlafaxine than to codeine and delivers analgesia by not only delivering "opioid-like" effects (through mild agonism of the μ-opioid receptor) but also by acting as a weak but fast-acting serotonin releasing agent and norepinephrine reuptake inhibitor. Tapentadol, with some structural similarities to tramadol, presents what is believed to be a novel drug working through two (and possibly three) different modes of action in the fashion of both a traditional opioid and as an SNRI. The effects of serotonin and norepinephrine on pain, while not completely understood, have had causal links established and drugs in the SNRI class are commonly used in conjunction with opioids (especially tapentadol and tramadol) with greater success in pain relief. Dosing of all opioids may be limited by opioid toxicity (e.g., confusion, respiratory depression, myoclonic jerks, and pinpoint pupils), seizures (particularly from tramadol), but opioid-tolerant individuals usually have higher dose ceilings than patients without tolerance. Opioids, while very effective analgesics, may have some unpleasant side-effects.
== Geography == Sanlúcar de Barrameda is located on the Atlantic coast of the autonomous community of Andalusia, in the province of Cadiz, specifically on the left side of the mouth of the Guadalquivir River, which separates the provinces of Huelva and Seville. The municipality covers an area of 174.3 km2 with 6 km of beaches. The city is part of the tourist area known as the Costa de la Luz (Coast of the Light), about 44 km from the provincial capital of Cádiz. This includes the marshes of the Pinar de la Bonanza Algaida and the marshes of the Guadalquivir, part of the Doñana Natural Park. Sanlúcar de Barrameda borders the municipalities of Trebujena, Jerez de la Frontera, Rota, Puerto de Santa María, and Chipiona. Its topography is shown in the MTN50 sheet (scale 1:50,000) No. 1047 of the National Topographic Map.
Sources: en.wikipedia.org
==== Neural ==== Oxytocin secretion in response to suckling or vagino-cervical stimulation is mediated by some of these pathways; vasopressin secretion in response to cardiovascular stimuli arising from chemoreceptors in the carotid body and aortic arch, and from low-pressure atrial volume receptors, is mediated by others. In the rat, stimulation of the vagina also causes prolactin secretion, and this results in pseudo-pregnancy following an infertile mating. In the rabbit, coitus elicits reflex ovulation. In the sheep, cervical stimulation in the presence of high levels of estrogen can induce maternal behavior in a virgin ewe. These effects are all mediated by the hypothalamus, and the information is carried mainly by spinal pathways that relay in the brainstem. Stimulation of the nipples stimulates release of oxytocin and prolactin and suppresses the release of LH and FSH. Cardiovascular stimuli are carried by the vagus nerve. The vagus also conveys a variety of visceral information, including for instance signals arising from gastric distension or emptying, to suppress or promote feeding, by signalling the release of leptin or gastrin, respectively. Again, this information reaches the hypothalamus via relays in the brainstem. In addition, hypothalamic function is responsive to—and regulated by—levels of all three classical monoamine neurotransmitters, noradrenaline, dopamine, and serotonin (5-hydroxytryptamine), in those tracts from which it receives innervation.
=== Validity === SPINA-GBeta significantly correlates with the M value in glucose clamp studies and (better than HOMA-Beta) with the two-hour value in oral glucose tolerance testing (OGTT), glucose rise in OGTT, subscapular skinfold, truncal fat content and the HbA1c fraction. It has the additional advantage that it circumvents the HOMA-blind zone, which renders the calculation of HOMA-Beta impossible if the fasting glucose concentration is 3.5 mmol/L (63 mg/dL) or below. Unlike HOMA-Beta, SPINA-Beta can be sensibly calculated in the whole range of measurements.
His rare non-comedic film roles include two collaborations with Andre Gregory and Louis Malle: the semi-autobiographical dialogue My Dinner with Andre, and a combined production-and-backstage-drama of Uncle Vanya titled Vanya on 42nd Street. Shawn quite often appears on television, where he has appeared in many genres and series. He has had recurring roles as the Grand Nagus Zek on Star Trek: Deep Space Nine, Stuart Best on Murphy Brown, Jeff Engels on The Cosby Show, Dr. Howard Stiles on Crossing Jordan, Arnie Ross on Taxi, Charles Lester on both The Good Wife and The Good Fight, a reprisal of his role as Mr. Hall on Clueless (based on the film), and Father Frank Ignatius on Evil. He appeared in the 1985 music video for Chaka Khan's "This Is My Night". On February 4, 2010, Shawn appeared as Alan Rubin on The Daily Show with Jon Stewart. A Master Builder opened in New York City in June 2014. In 2018, he joined the cast of Young Sheldon in the recurring role of Meemaw's boyfriend and Sheldon's physics professor, Dr. John Sturgis. Shawn starred in Woody Allen's 2020 film Rifkin's Festival, set in San Sebastián, Spain. Shawn was honored in 2005 with the PEN/Laura Pels International Foundation for Theater Award as a Master American Dramatist.
But the PEF executive board retroactively approved the sick leave buybacks in a private meeting in August 1999, forcing Benson to drop the lawsuit. Nonetheless, former PEF Secretary-Treasurer Patricia Ford was convicted of bribery in June 2003. Benson was re-elected without opposition in late 2000. He and his slate of officers were easily renominated, while an opponent received only 17 of the necessary 4,998 signatures needed to run for office. During Benson's second term, several PEF members died during the September 11 attacks on New York City. Of the 300 PEF members who worked in the World Trade Center, 34 were killed in the attack. One of PEF's larger campaigns during Benson's time in office was fighting health care cutbacks in New York state. For several years, the union protested against staff layoffs and the closure of hospitals and other health care facilities. PEF also sought increases in the number of health care workers on staff, an end to mandatory overtime, and minimum worker-to-patient staffing ratios. Benson was re-elected without opposition to a third term in 2003, the first time any PEF president had been elected to a third term. Benson immediately entered into negotiations for a new contract after his re-election. Initially, PEF had hopes for easier contract negotiations after Governor Pataki fulfilled a promise to give PEF members three additional days of sick leave per year. But after working without a contract for a year, PEF members found that Pataki proposed contract concessions in order to bring the state's budget into balance.
If recovery of usable ruthenium is a goal, an extremely pure technetium target is needed; if small traces of the minor actinides such as americium and curium are present in the target, they are likely to undergo fission and form more fission products which increase the radioactivity of the irradiated target. The formation of ruthenium-106 (half-life 374 days) from the 'fresh fission' is likely to increase the activity of the final ruthenium metal, which will then require a longer cooling time after irradiation before the ruthenium can be used. The actual separation of technetium-99 from spent nuclear fuel is a long process. During fuel reprocessing, it comes out as a component of the highly radioactive waste liquid. After sitting for several years, the radioactivity reduces to a level where extraction of the long-lived isotopes, including technetium-99, becomes feasible. A series of chemical processes yields technetium-99 metal of high purity.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.